| General Information | |
|---|---|
| ZINC ID | ZINC000001490840 |
| Molecular Weight (Da) | 550 |
| SMILES | C[C@H](NC(=O)C(F)(F)F)c1ccc(S(=O)(=O)c2ccc(Cl)cc2S(=O)(=O)c2ccccc2F)cc1 |
| Molecular Formula | C22Cl1F4N1O5S2 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 121.489 |
| HBA | 5 |
| HBD | 1 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 35 |
| LogP | 5.498 |
| Activity (Ki) in nM | 3.7154 |
| Polar Surface Area (PSA) | 114.14 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | + |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.842 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.14 |
| Ilogp | 3.29 |
| Xlogp3 | 4.87 |
| Wlogp | 8.4 |
| Mlogp | 4.61 |
| Silicos-it log p | 4.65 |
| Consensus log p | 5.17 |
| Esol log s | -6.17 |
| Esol solubility (mg/ml) | 0.000372 |
| Esol solubility (mol/l) | 0.00000067 |
| Esol class | Poorly sol |
| Ali log s | -7 |
| Ali solubility (mg/ml) | 0.0000548 |
| Ali solubility (mol/l) | 9.96E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.26 |
| Silicos-it solubility (mg/ml) | 0.0000003 |
| Silicos-it solubility (mol/l) | 5.47E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.2 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.54 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.087 |
| Logd | 3.181 |
| Logp | 4.302 |
| F (20%) | 0.001 |
| F (30%) | 0.001 |
| Mdck | - |
| Ppb | 98.73% |
| Vdss | 0.487 |
| Fu | 1.27% |
| Cyp1a2-inh | 0.185 |
| Cyp1a2-sub | 0.627 |
| Cyp2c19-inh | 0.884 |
| Cyp2c19-sub | 0.929 |
| Cl | 1.326 |
| T12 | 0.017 |
| H-ht | 0.942 |
| Dili | 0.997 |
| Roa | 0.14 |
| Fdamdd | 0.97 |
| Skinsen | 0.022 |
| Ec | 0.003 |
| Ei | 0.007 |
| Respiratory | 0.017 |
| Bcf | 0.3 |
| Igc50 | 3.597 |
| Lc50 | 3.621 |
| Lc50dm | 5.233 |
| Nr-ar | 0.006 |
| Nr-ar-lbd | 0.021 |
| Nr-ahr | 0.065 |
| Nr-aromatase | 0.028 |
| Nr-er | 0.398 |
| Nr-er-lbd | 0.015 |
| Nr-ppar-gamma | 0.006 |
| Sr-are | 0.739 |
| Sr-atad5 | 0.003 |
| Sr-hse | 0.002 |
| Sr-mmp | 0.789 |
| Sr-p53 | 0.006 |
| Vol | 468.481 |
| Dense | 1.172 |
| Flex | 0.348 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 1 |
| Nonbiodegradable | 2 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.442 |
| Synth | 2.975 |
| Fsp3 | 0.136 |
| Mce-18 | 54 |
| Natural product-likeness | -1.46 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |